Optimizing therapy for Candida infections

Seminars in Respiratory and Critical Care Medicine

Volumn 28, Issue 6, 2007, Pages 678-688

  Playford, Elliott Geoffrey ^a,b   Sorrell, Tania C ^b,c  

^a PRINCESS ALEXANDRA HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c WESTMEAD HOSPITAL   (Australia)

Author keywords

Antifungal therapy; Candidemia; Invasive candidiasis

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; ASTEMIZOLE; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CASPOFUNGIN; CISAPRIDE; CYCLOSPORIN; ECHINOCANDIN; FLUCONAZOLE; ITRACONAZOLE; MICAFUNGIN; PHENOBARBITAL; PHENYTOIN; POSACONAZOLE; RAPAMYCIN; RIFABUTIN; RIFAMPICIN; RITONAVIR; SULFONYLUREA DERIVATIVE; TACROLIMUS; TERFENADINE; THEOPHYLLINE; TRIAZOLE DERIVATIVE; UNINDEXED DRUG; VORICONAZOLE; WARFARIN;

AMINOTRANSFERASE BLOOD LEVEL; ANTIFUNGAL RESISTANCE; CHILL; CLINICAL TRIAL; CONFUSION; CREATININE BLOOD LEVEL; CRITICAL ILLNESS; CRITICALLY ILL PATIENT; DRUG WITHDRAWAL; FEVER; GASTROINTESTINAL SYMPTOM; HALLUCINATION; HEADACHE; HUMAN; INFECTION PREVENTION; INFECTION SENSITIVITY; INTENSIVE CARE UNIT; INVASIVE CANDIDIASIS; LOADING DRUG DOSE; NEPHROTOXICITY; PRIORITY JOURNAL; RASH; REVIEW; SIDE EFFECT; SKIN MANIFESTATION; THROMBOPHLEBITIS; TREATMENT DURATION; VISUAL DISORDER;

ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; CROSS INFECTION; DRUG RESISTANCE, FUNGAL; EQUIPMENT CONTAMINATION; HUMANS; INTENSIVE CARE UNITS;

EID: 37649000997     PISSN: 10693424     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-996415     Document Type: Review

References (87)

1. Ostrosky-Zeichner L, Pappas P. Invasive candidiasis in the intensive care unit. Crit Care Med 2006;34:857-863
2. Eggimann P, Garbino J, Pittet D. Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect Dis 2003;3:685-702
3. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004;39:309-317
4. Richards MJ, Edwards JR, Culver DH, Gaynes RP. Nosocomial infections in medical intensive care units in the United States. Crit Care Med 1999;27:887-892
5. Richards MJ, Edwards JR, Culver DH, Gaynes RP. Nosocomial infections in combined medical-surgical intensive care units in the United States. Infect Control Hosp Epidemiol 2000;21:510-515
6. Jarvis WR, Edwards JR, Culver DH, et al. Nosocomial infection rates in adult and pediatric intensive care units in the United States. Am J Med 1991;91:185S-191S
7. Marchetti O, Bille J, Fluckiger U, et al. Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991-2000. Clin Infect Dis 2004;38:311-320
8. Rangel-Frausto MS, Wiblin T, Blumberg HM, et al. National epidemiology of mycoses survey (NEMIS): variations in rates of bloodstream infections due to Candida species in seven surgical intensive care units and six neonatal intensive care units. Clin Infect Dis 1999;29:253-258
9. Leleu G, Aegerter P, Guidet B. Systemic candidiasis in intensive care units: a multicenter, matched-cohort study. J Crit Care 2002;17:168-175
10. Beck-Sague C, Jarvis WR. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. J Infect Dis 1993;167:1247-1251
11. Trick WE, Fridkin SK, Edwards JR, Hajjeh RA, Gaynes RP. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin Infect Dis 2002;35:627-630
12. Pelz RK, Lipsett PA, Swoboda SM, et al. Candida infections: outcome and attributable ICU costs in critically ill patients. J Intensive Care Med 2000;15:255-261
13. Rentz AM, Halpern MT, Bowden R. The impact of candidemia on length of hospital stay, outcome, and overall cost of illness. Clin Infect Dis 1998;27:781-788
14. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007;20:133-163
15. Montravers P, Dupont H, Gauzit R, et al. Candida as a risk factor for mortality in peritonitis. Crit Care Med 2006;34: 646-652
16. Pappas PG, Rex JH, Sobel JD, et al. Guidelines for treatment of candidiasis. Clin Infect Dis 2004;38:161-189
17. Groll AH, Gea-Banacloche JC, Glasmacher A, Just-Nuebling G, Maschmeyer G, Walsh TJ. Clinical pharmacology of antifungal compounds. Infect Dis Clin North Am 2003;17: 159-191
18. Eggimann P, Garbino J, Pittet D. Management of Candida species infections in critically ill patients. Lancet Infect Dis 2003;3:772-785
19. Girois SB, Chapuis F, Decullier E, Revol BGP. Adverse effects of antifungal therapies in invasive fungal infections: review and meta-analysis. Eur J Clin Microbiol Infect Dis 2006;25:138-149
20. Kulemann V, Bauer M, Graninger W, Joukhadar C. Safety and potential of drug interactions of caspofungin and voriconazole in multimorbid patients. Pharmacology 2005; 75:165-178
21. Rex JH, Bennett JE, Sugar AM, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N Engl J Med 1994;331:1325-1330
22. Phillips P, Shafran S, Garber G, et al. Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Eur J Clin Microbiol Infect Dis 1997;16:337-345
23. Kullberg BJ, Sobel JD, Ruhnke M, et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 2005;366:1435-1442
24. Anaissie EJ, Darouiche RO, Abi-Said D, et al. Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature. Clin Infect Dis 1996; 23:964-972
25. Kontoyiannis DP, Bodey GP, Mantzoros CS. Fluconazole vs. amphotericin B for the management of candidaemia in adults: a meta-analysis. Mycoses 2001;44:125-135
26. Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002;347:2020-2029
27. Kuse E-R, Chetchotisakd P, da Cunha CA, et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 2007;369:1519-1527
28. Reboli AC, Rotstein C, Pappas PG, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007;356:2472-2482
29. Betts RF, Rotstein C, Talwar D, et al. Comparison of micafungin and caspofungin for candidemia or invasive candidiasis (IC). In: Program and Abstracts of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco: American Society for Microbiology; 2006: abstract M-1308a
30. Anaissie EJ, White M, Uzon O, et al. Amphotericin B lipid complex versus amphotericin B for treatment of invasive candidiasis: a prospective, randomized, multicenter trial. In: 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco: American Society for Microbiology; 1996: abstract LM21
31. Rex JH, Pappas PG, Karchmer AW, et al. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. [see comment] Clin Infect Dis 2003;36:1221-1228
32. Sobel JD, Revankar SG. Echinocandins: first choice or first-line therapy for invasive candidiasis? N Engl J Med 2007; 356:2525-2526
33. Pachl J, Svoboda P, Jacobs F, et al. A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis, [see comment]. Clin Infect Dis 2006;42:1404-1413
34. Herbrecht R, Fohrer C, Nivoix Y. Mycograb for the treatment of invasive candidiasis. Clin Infect Dis 2006;43: 1083-4
35. Lipsett PA. Surgical critical care: fungal infections in surgical patients. Crit Care Med 2006;34:S215-S224
36. Shorr AF, Lazarus DR, Sherner JH, et al. Do clinical features allow for accurate prediction of fungal pathogenesis in bloodstream infections? Potential implications of the increasing prevalence of non-albicans candidemia. Crit Care Med 2007;35:1077-1083
37. Trotman RL, Williamson JC, Shoemaker DM, Salzer WL. Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. Clin Infect Dis 2005; 41:1159-1166
38. von Mach MA, Burhenne J, Weilemann LS. Accumulation of the solvent vehicle sulphobutylether beta cyclodextrin sodium in critically ill patients treated with intravenous voriconazole under renal replacement therapy. BMC Clin Pharmacol 2006;6:6
39. Muhl E. Antimycotic drugs under continuous renal replacement therapy. Mycoses 2005;48:56-60
40. Mohammedi I, Piens MA, Padoin C, Robert D. Plasma levels of voriconazole administered via a nasogastric tube to critically ill patients. Eur J Clin Microbiol Infect Dis 2005; 24:358-360
41. Harbarth S, Pestotnik SL, Lloyd JF, Burke JP, Samore MH. The epidemiology of nephrotoxicity associated with conventional amphotericin B therapy. Am J Med 2001;111:528-534
42. Harbarth S, Burke JP, Lloyd JF, Evans RS, Pestotnik SL, Samore MH. Clinical and economic outcomes of conventional amphotericin B-associated nephrotoxicity. Clin Infect Dis 2002;35:e120-e127
43. Bates DW, Su L, Yu DT. Mortality and costs associated with amphotericin B therapy. Clin Infect Dis 2001;32:686-693
44. Anderson CM. Sodium chloride treatment of amphotericin B nephrotoxicity: standard of care? West J Med 1995;162: 313-317
45. Eriksson U, Seifert B, Schaffner A. Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial. BMJ 2001;322:579-582
46. Kleinberg M. What is the current and future status of conventional amphotericin B? Int J Antimicrob Agents 2006; 27(Suppl 1):12-16
47. Wingard JR, White MH, Anaissie E, et al. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. Clin Infect Dis 2000;31:1155-1163
48. Fleming RV, Kantarjian HM, Husni R, et al. Comparison of amphotericin B lipid complex (ABLC) vs. ambisome in the treatment of suspected or documented fungal infections in patients with leukemia. Leuk Lymphoma 2001;40:511-520
49. Brooks RG. Prospective study of Candida endophthalmitis in hospitalized patients with candidemia. Arch Intern Med 1989;149:2226-2228
50. Pappas PG. Invasive candidiasis. Infect Dis Clin North Am 2006;20:485-506
51. Rodriguez-Adrian LJ, King RT, Tamayo-Derat LG, Miller JW, Garcia CA, Rex JH. Retinal lesions as clues to disseminated bacterial and candidal infections: frequency, natural history, and etiology. Medicine 2003;82:187-202
52. Ostrosky-Zeichner L, Rex JH, Pappas PG, et al. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother 2003;47: 3149-3154
53. Rex JH, Pfaller MA, Barry AL, Nelson PW, Webb CD. Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia. Antimicrob Agents Chemother 1995;39:40-44
54. Malani A, Hmoud J, Chiu L, Carver PL, Bielaczyc A, Kauffman CA. Candida glabrata fungemia: experience in a tertiary care center. Clin Infect Dis 2005;41:975-981
55. Nucci M, Anaissie E. Revisiting the source of candidemia: skin or gut? Clin Infect Dis 2001;33:1959-1967
56. Bross J, Talbot GH, Maislin G, Hurwitz S, Strom BL. Risk factors for nosocomial candidemia: a case-control study in adults without leukemia. Am J Med 1989;87:614-620
57. Blumberg HM, Jarvis WR, Soucie JM, et al. Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. Clin Infect Dis 2001;33:177-186
58. McKinnon PS, Goff DA, Kern JW, et al. Temporal assessment of Candida risk factors in the surgical intensive care unit. Arch Surg 2001;136:1401-1408
59. Anaissie EJ, Rex JH, Uzun O, Vartivarian S. Predictors of adverse outcome in cancer patients with candidemia. Am J Med 1998;104:238-245
60. Nucci M, Anaissie E. Should vascular catheters be removed from all patients with candidemia? An evidence-based review. Clin Infect Dis 2002;34:591-599
61. Rex JH, Bennett JE, Sugar AM, et al. Intravascular catheter exchange and duration of candidemia. Clin Infect Dis 1995; 21:994-996
62. Walsh TJ, Rex JH. All catheter-related candidemia is not the same: assessment of the balance between the risks and benefits of removal of vascular catheters. Clin Infect Dis 2002;34:600-602
63. Mermel LA, Farr BM, Sherertz RJ, et al. Guidelines for the management of intravascular catheter-related infections. Clin Infect Dis 2001;32:1249-1272
64. Bennett JE. Echinocandins for candidemia in adults without neutropenia. N Engl J Med 2006;355:1154-1159
65. Oude Lashof AM, Donnelly JP, Meis JF, van der Meer JW, Kullberg BJ. Duration of antifungal treatment and development of delayed complications in patients with candidaemia. Eur J Clin Microbiol Infect Dis 2003;22:43-48
66. Garey KW, Rege M, Pai MP, et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 2006; 43:25-31
67. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005;49: 3640-3645
68. Chen SC, Halliday CL, Meyer W. A review of nucleic acid-based diagnosis tests for systemic mycoses with an emphasis on polymerase chain reaction-based assays. Med Mycol 2002; 40:333-357
69. Yeo SF, Wong B. Current status of nonculture methods for diagnosis of invasive fungal infections. Clin Microbiol Rev 2002;15:465-484
70. Obayashi T, Toshida M, Mori T, et al. Plasma (1- > 3)-β-D-glucan measurement in diagnosis of invasive deep mycosis and fungal febrile episodes. Lancet 1995;345:17-20
71. Odabasi Z, Mattiuzzi G, Estey E, et al. Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis 2004;39:199-205
72. Takesue Y, Kakehashi M, Ohge H, et al. Combined assessment of beta-D-glucan and degree of candida colonization before starting empiric therapy for candidiasis in surgical patients. World J Surg 2004;28:625-630
73. Digby J, Kalbfleisch J, Glenn A, Larsen A, Browder W, Williams D. Serum glucan levels are not specific for presence of fungal infections in intensive care unit patients. Clin Diagn Lab Immunol 2003;10:882-885
74. Pickering JW, Sant HW, Bowles CAP, Roberts WL, Woods GL. Evaluation of a (1 - > 3)-beta-D-glucan assay for diagnosis of invasive fungal infections. J Clin Microbiol 2005;43: 5957-5962
75. Ostrosky-Zeichner L. New approaches to the risk of Candida in the intensive care unit. Curr Opin Infect Dis 2003;16:533-537
76. Pittet D, Monod M, Suter PM, Frenk E, Auckenthaler R. Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg 1994;220:751-758
77. Magill SS, Swoboda SM, Johnson EA, et al. The association between anatomic site of Candida colonization, invasive candidiasis, and mortality in critically ill surgical patients. Diagn Microbiol Infect Dis 2006;55:293-301
78. Paphitou NI, Ostrosky-Zeichner L, Rex J. Rules for identifiying patients at increased risk for candidal infections in the surgical intensive care unit: approach to developing practical criteria for systemic use in antifungal prophylaxis trials. Med Mycol 2005;43:235-243
79. Leon C, Ruiz-Santana S, Saavedra S, et al. A bedside scoring system ("Candida score") for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization. Crit Care Med 2006;34:730-737
80. Piarroux R, Grenouillet F, Balvay P, et al. Assessment of preemptive treatment to prevent severe candidiasis in critically ill surgical patients. Crit Care Med 2004;32:2443-2449
81. Dupont H, Bourichon A, Paugam-Burtz C, Mantz J, Desmonts J-M. Can yeast isolation in peritoneal fluid be predicted in intensive care unit patients with peritonitis. Crit Care Med 2003;31:752-757
82. Michalopoulos AS, Geroulanos S, Mentzelopoulos SD. Determinants of candidemia and candidemia-related death in cardiothoracic ICU patients. Chest 2003;124:2244-2255
83. Ostrosky-Zeichner L, Sable C, Sobel J, et al. Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting. Eur J Clin Microbiol Infect Dis 2007; 26:271-276
84. Playford EG, Webster AC, Sorrell TC, Craig JC. Antifungal agents for preventing fungal infections in non-neutropenic critically ill and surgical patients: systematic review and meta-analysis of randomized clinical trials. J Antimicrob Chemother 2006;57:628-638
85. Golan Y, Wolf MP, Pauker SG, Wong JB, Hadley S. Empirical anti-Candida therapy among selected patients in the intensive care unit: a cost-effectiveness analysis. Ann Intern Med 2005;143:857-869
86. Eggimann P, Calandra T, Fluckiger U, et al. Invasive candidiasis: comparison of management choices by infectious diseases and critical care specialists. Intensive Care Med 2005; 31:1514-1517
87. Garey KW, Neuhauser MM, Bearden DT, et al. Evaluation of antifungals in the surgical intensive care unit: a multiinstitutional study. Mycoses 2006;49:226-231